Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion

被引:0
作者
Tomohiro Kawaguchi
Yukihiko Sonoda
Ichiyo Shibahara
Ryuta Saito
Masayuki Kanamori
Toshihiro Kumabe
Teiji Tominaga
机构
[1] Tohoku University Graduate School of Medicine,Department of Neurosurgery
[2] Yamagata University School of Medicine,Department of Neurosurgery, Faculty of Medicine
[3] Kitasato University School of Medicine,Department of Neurosurgery
来源
Journal of Neuro-Oncology | 2016年 / 129卷
关键词
Glioma; WHO grade III; IDH; 1p/19q; Surgery; Magnetic resonance imaging;
D O I
暂无
中图分类号
学科分类号
摘要
The prognosis of patients with WHO grade III gliomas is highly dependent on their genomic status such as the isocitrate dehydrogenase (IDH) 1/2 mutation and1p/19q co-deletion. However, difficulties have been associated with determining which tumors have certain genomic profiles by preoperative radiographical modalities, and the role of surgical resection in achieving better outcomes remains unclear. This retrospective study included 124 consecutive patients with newly diagnosed grade III gliomas. The genomic status of IDH1/2 and 1p/19q was analyzed in these patients. Tumors were then divided into 3 subgroups based on their genomic status; the IDH 1/2 mutation with the 1p/19q co-deletion (1p/19q co-del), the IDH 1/2 mutation without the 1p/19q co-deletion (non-1p/19q co-del), and the IDH 1/2 wild type (IDH wt). Survival times were compared between patients who underwent gross total resection and those who did not (GTR versus non-GTR). The relationships between genomic statuses and MR imaging characteristics such as ring-like or nodular enhancements by gadolinium, and very low intensity on T1-weighted images with blurry enhancements (T1VL) were also examined. Among all patients with grade III gliomas, GTR patients had longer median survival and progression-free times than those of non-GTR patients (undefined versus 87 months, p = 0.097, and 124 versus 34 months, p = 0.059, respectively). No significant differences were observed in survival between GTR and non-GTR patients in the 1p/19q co-del group (p = 0.14), or between GTR and non-GTR patients in the IDH wt group (26 and 27 months, p = 0.29). On the other hand, in non-1p/19q co-del group, survival was significantly longer in GTR patients than in non-GTR patients (undefined versus 77 months, p = 0.005). Radiographically, T1VL was detected in most tumors in the non-1p/19q co-del group (78.2 %), but only 6 (21.4 %) and 17 (41.5 %) tumors in the 1p/19q co-del and IDH wt groups, respectively. A correlation was not found between other genomic subgroups and MR imaging findings. Strict surgical removal is important to improve the prognosis of patients with grade III gliomas, especially for tumors with the IDH 1/2 mutation without the 1p/19q co-deletion. The MR finding of T1VL can be used to select candidates for more radical resection.
引用
收藏
页码:505 / 514
页数:9
相关论文
共 50 条
  • [31] Does ATRX immunohistochemistry deserve a surrogate of 1p/19q codel in grade II, III gliomas?
    Yamamichi, Akane
    Ohka, Fumiharu
    Aoki, Kosuke
    Suzuki, Hiromichi
    Hirano, Masaki
    Motomura, Kazuya
    Wakabayashi, Toshihiko
    Kato, Yukinari
    Natsume, Atsushi
    CANCER SCIENCE, 2018, 109 : 926 - 926
  • [32] A novel fully automated MRI-based deep-learning method for classification of 1p/19q co-deletion status in brain gliomas
    Yogananda, Chandan Ganesh Bangalore
    Shah, Bhavya R.
    Yu, Frank F.
    Pinho, Marco C.
    Nalawade, Sahil S.
    Murugesan, Gowtham K.
    Wagner, Benjamin C.
    Mickey, Bruce
    Patel, Toral R.
    Fei, Baowei
    Madhuranthakam, Ananth J.
    Maldjian, Joseph A.
    NEURO-ONCOLOGY ADVANCES, 2020, 2 (SUPP 4) : 42 - 48
  • [33] TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations
    Arita, Hideyuki
    Matsushita, Yuko
    Machida, Ryunosuke
    Yamasaki, Kai
    Hata, Nobuhiro
    Ohno, Makoto
    Yamaguchi, Shigeru
    Sasayama, Takashi
    Tanaka, Shota
    Higuchi, Fumi
    Iuchi, Toshihiko
    Saito, Kuniaki
    Kanamori, Masayuki
    Matsuda, Ken-ichiro
    Miyake, Yohei
    Tamura, Kaoru
    Tamai, Sho
    Nakamura, Taishi
    Uda, Takehiro
    Okita, Yoshiko
    Fukai, Junya
    Sakamoto, Daisuke
    Hattori, Yasuhiko
    Pareira, Eriel Sandika
    Hatae, Ryusuke
    Ishi, Yukitomo
    Miyakita, Yasuji
    Tanaka, Kazuhiro
    Takayanagi, Shunsaku
    Otani, Ryohei
    Sakaida, Tsukasa
    Kobayashi, Keiichi
    Saito, Ryuta
    Kurozumi, Kazuhiko
    Shofuda, Tomoko
    Nonaka, Masahiro
    Suzuki, Hiroyoshi
    Shibuya, Makoto
    Komori, Takashi
    Sasaki, Hikaru
    Mizoguchi, Masahiro
    Kishima, Haruhiko
    Nakada, Mitsutoshi
    Sonoda, Yukihiko
    Tominaga, Teiji
    Nagane, Motoo
    Nishikawa, Ryo
    Kanemura, Yonehiro
    Kuchiba, Aya
    Narita, Yoshitaka
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2020, 8 (01)
  • [34] TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations
    Hideyuki Arita
    Yuko Matsushita
    Ryunosuke Machida
    Kai Yamasaki
    Nobuhiro Hata
    Makoto Ohno
    Shigeru Yamaguchi
    Takashi Sasayama
    Shota Tanaka
    Fumi Higuchi
    Toshihiko Iuchi
    Kuniaki Saito
    Masayuki Kanamori
    Ken-ichiro Matsuda
    Yohei Miyake
    Kaoru Tamura
    Sho Tamai
    Taishi Nakamura
    Takehiro Uda
    Yoshiko Okita
    Junya Fukai
    Daisuke Sakamoto
    Yasuhiko Hattori
    Eriel Sandika Pareira
    Ryusuke Hatae
    Yukitomo Ishi
    Yasuji Miyakita
    Kazuhiro Tanaka
    Shunsaku Takayanagi
    Ryohei Otani
    Tsukasa Sakaida
    Keiichi Kobayashi
    Ryuta Saito
    Kazuhiko Kurozumi
    Tomoko Shofuda
    Masahiro Nonaka
    Hiroyoshi Suzuki
    Makoto Shibuya
    Takashi Komori
    Hikaru Sasaki
    Masahiro Mizoguchi
    Haruhiko Kishima
    Mitsutoshi Nakada
    Yukihiko Sonoda
    Teiji Tominaga
    Motoo Nagane
    Ryo Nishikawa
    Yonehiro Kanemura
    Aya Kuchiba
    Yoshitaka Narita
    Acta Neuropathologica Communications, 8
  • [35] Multipool-CEST and CEST-based pH assessment as predictive tools for glioma grading, IDH mutation, 1p/19q codeletion, and MGMT promoter methylation in gliomas
    Zhang, Xinli
    Lu, Jue
    Liu, Xiaoming
    Sun, Peng
    Qin, Qian
    Xiang, Zhengdong
    Cheng, Lan
    Zhang, Xiaoxiao
    Guo, Xiaotong
    Wang, Jing
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [36] Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas
    Yamauchi, Takahiro
    Ohno, Makoto
    Matsushita, Yuko
    Takahashi, Masamichi
    Miyakita, Yasuji
    Kitagawa, Yosuke
    Kondo, Erika
    Tsushita, Natsuko
    Satomi, Kaishi
    Yoshida, Akihiko
    Ichimura, Koichi
    Narita, Yoshitaka
    BRAIN TUMOR PATHOLOGY, 2018, 35 (03) : 148 - 158
  • [37] The correlation analysis of TERT promoter mutations with IDH1/2 mutations and 1p/19q detected in human gliomas
    Xu, Jie
    Xu, Fang-Ping
    Liu, Zhi-Hua
    Cui, Qian
    Zhang, Ke-Ping
    Li, Zhi
    MEDICINE, 2022, 101 (29) : E29668
  • [38] Radiogenomic analysis: 1p/19q codeletion based subtyping of low-grade glioma by analysing advanced biomedical texture descriptors
    Gore, Sonal
    Jagtap, Jayant
    JOURNAL OF KING SAUD UNIVERSITY-COMPUTER AND INFORMATION SCIENCES, 2022, 34 (10) : 8449 - 8458
  • [39] Predicting 1p/19q co-deletion status from magnetic resonance imaging using deep learning in adult-type diffuse lower-grade gliomas: a discovery and validation study
    Yan, Jing
    Zhang, Shenghai
    Sun, Qiuchang
    Wang, Weiwei
    Duan, Wenchao
    Wang, Li
    Ding, Tianqing
    Pei, Dongling
    Sun, Chen
    Wang, Wenqing
    Liu, Zhen
    Hong, Xuanke
    Wang, Xiangxiang
    Guo, Yu
    Li, Wencai
    Cheng, Jingliang
    Liu, Xianzhi
    Li, Zhi-Cheng
    Zhang, Zhenyu
    LABORATORY INVESTIGATION, 2022, 102 (02) : 154 - 159
  • [40] Evaluation of chromosome 1p/19q deletion by Fluorescence in Situ Hybridization (FISH) as prognostic factors in malignant glioma patients on treatment with alkylating chemotherapy
    Pandith, Arshad A.
    Zahoor, Wani
    Manzoor, Usma
    Nisar, Syed
    Guru, Faisal R.
    Naikoo, Niyaz A.
    ul Aein, Qurat
    Baba, Shahid M.
    Bhat, Abdul R.
    Ganai, Farooq
    Shah, Parveen
    CANCER GENETICS, 2023, 278 : 55 - 61